A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

Australia ‘undervalues’ the products of drug companies, Pfizer has told the Productivity Commission, echoing US lobbyists ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average dividend payer in the S&P 500. If it can't maintain its payout-raising streak, ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...

The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine, immunology, inflammation and vaccines. Over the past decade, Pfizer has ...